Pulmatrix Regains Rights to PUR1800 for COPD, Phase 2 Trial Planned

Pulmatrix Regains Rights to PUR1800 for COPD, Phase 2 Trial Planned

292150

Pulmatrix Regains Rights to PUR1800 for COPD, Phase 2 Trial Planned

Pulmatrix will regain full rights to its portfolio of narrow spectrum kinase inhibitor (NSKI) medications, including the investigational therapy PUR1800 to treat acute flare in chronic obstructive pulmonary disease (COPD) and other chronic diseases of the airways. The announcement follows the ending of a license, development, and commercialization agreement with Johnson & Johnson’s Enterprise Innovation, which funded the PUR1800 program, including ongoing Phase 1b and long-term toxicology studies. Pulmatrix stated it intends to continue developing…

You must be logged in to read/download the full post.